Next Phase Newsletter

The corporate venture arm of a senior living community invests strategically in companies that can enhance their services or the elderly population quality of life in general, including in healthcare. Within healthcare, the firm is willing to invest in digital health, medical devices and diagnostic/monitoring technologies, but will not invest in therapeutics. The firm generally invests in seed to series A, and will occasionally act as a company builder, co-founding a company around a promising technology. In an initial investment, the firm will generally invest no more than $.5M, but has the ability to invest in follow-on rounds. As a strategic investor, in addition to capital, the firm can employ their facilities for pilot programs, and will occasionally do so before investing. The firm is primarily interested in Israeli companies, but will invest globally.

The firm invests in multiple sectors related to the elderly population quality of life. These technologies can include medical devices, diagnostics and digital health technologies. Examples include chronic disease management software or monitoring devices.

The firm invests in multiple sectors related to the elderly population quality of life. These technologies can include medical devices, diagnostics and digital health technologies. Examples include chronic disease management software or monitoring devices.
 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The holding company of a large corporation is dedicated to fostering innovation across by investing in and partnering with strategic startups. The corporate venture capital arm is open to global opportunities and is geography and stage agnostic, but has specific preferences depending on the technology sector.

Healthcare/Medical is one of the major focus areas of the firm. The corporate venture capital arm is interested therapeutics solutions such as solutions beyond the pill (digital therapeutics) and around the pill (delivery systems etc). Therapeutics areas of interest are CNS, Autoimmune diseases, metabolic diseases, regenerative medicine, Aging related solutions and Vaccines. The corporate venture capital arm is also interested in diagnostics solutions based on genomics, metagenomics, metabolomics, healthcare ICT (biosensors etc), and medical big data. Furthermore, medical devices for wound care, bone cement and hospital related infection treatment is also is an area of interest and is open to all classes of medical devices including 510k and PMA.

The corporate venture capital arm has a close, collaborative relationship with other business branches within the corporation, and can also present opportunities to the pharma branch, CRO, CDMO branches as appropriate.

The firm is a flexible investor and does not require companies to have a Japan-centric angle. For medical device & digital therapeutics opportunities, the group does prefer technologies with strong promise in the US market. The venture group has a close relationship with all other business operations within the corporation and can actively support companies by leveraging these relationships.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A transatlantic advisory and investment firm based in USA and Europe advises and invests exclusively in the life science space. The firm brings together early-stage US and EU based life science companies to bridge the Atlantic, gain scale and de-risk. It helps negotiate collaboration agreements and a road map towards a merger. The firm investment arm will invest $2-6M in the form of equity or convertible notes, for the most promising newly merged entities, by turning to a group of pledge investors. In the future, the firm is looking to raise a $100M transatlantic fund comprised of US and EU based sister funds that would invest jointly in the merged entities.

The firm seeks companies in all four life science sectors including therapeutics, medical devices, diagnostics, and digital health and is agnostic to both subsector and indication. The firm is open to preclinical and pre-prototype companies and all three classes of medical devices.

The firm’s whole focus is to bring together US and European teams, and starts the process by contacting companies looking to cross the Atlantic and establish a presence via a partnership. The firm looks for companies with a solid core team and the bandwidth to negotiate and build a transatlantic partnership that may evolve into a full-scale merger. The firm looks for companies in early stage, but not necessarily startups, since the core team is important. The firm also provides integration services to help the teams complement each other and work well together, a factor critical to the success of the merged entity. After engineering the merger, the firm will seek to take advantage of the significantly higher valuation to lead a new funding round. In these cases, the firm would seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in Canada was founded by an experienced healthcare investment team, who has a successful track record of identifying, building, and growing life science companies. The firm recently launched a $200M (CAD) fund, through which the firm will invest around 80% in Canada-based life science companies and 20% in USA/global companies. The firm will generally participate in Series A financing rounds and beyond, including crossover and IPO; average check sizes will be around $5-10M CAD, with a total of $15-20M CAD will be reserved for follow-on investments. In addition, the firm is also dedicated to company incubation and creation for which the firm will work with earlier stage companies and deploy smaller amounts of capital (around $1M CAD).

The firm has a general theme of investing in precision medicine – technologies that can enhance the quality and accuracy of diagnoses, enable more precise and personalized treatments, targeted therapies such as cell & gene therapy, technologies that leverage AI to accelerate therapeutic development, etc. In terms of sector, the firm seeks to invest 50-60% in therapeutics, 20-30% in medical devices, and 10-15% in AI/digital health/diagnostics. For medical devices, the firm prefers later stage opportunities that are close to commercialization. The firm does not focus on any particular indication area.

The firm does not have specific company or management team requirements. While the firm likes to see management teams with a successful track record and wide range of experiences, this is not required and the firm is open to working on inexperienced management teams. The firm is capable of leading or co-leading investment rounds, and is also open to co-investing with likeminded investors. The firm is very hands-on and leverages their network to actively support the growth of their portfolio companies and provide needed resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Founded in 2020 and based in California, the firm is a life science venture capital arm of a large real estate group. The firm is interested in therapeutic, medical device, diagnostic, and digital health technologies. The firm usually participates in Seed to series C financing rounds with check sizes between $500K – 2M USD. The firm is open to both leading and co-investing and is aiming to make 15 investments in the next 12 months. The firm is open to global opportunities.

The firm is open to considering innovative technologies that address unmet medical needs in therapeutics, diagnostics, medical devices, and digital health. The firm’s greatest interest lies in the biotech and diagnostic sector in which the firm have the strongest expertise. For medical devices and diagnostics, the firm is open to any subsectors but is most interested in AI-based diagnostics and innovative genomics applications. The firm  is open to any indication area including oncology, CNS diseases and rare diseases.

The firm seeks to work with companies with a sound business model and great execution, but will mainly focus on the merit of technologies and the team when working with very early-stage companies. The firm considers itself to be an active investor and will take a board seat depending on the cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A newly established venture capital firm was founded in 2020 and is based in Europe. The firm is currently raising its first fund targeting €30M, and expects to close in mid to late 2021 and become fully operative. The firm is actively seeking investment opportunities and performing due diligence on companies they identify as a fit with the firm. The firm’s focus is in Seed to Series A financings and initial size of investment will be around €500K, and can invest up to €2.5M over the life of investment. While the firm is open to USA-based opportunities, the firm will focus on those based in Europe, Israel, and Spain where the firm is based.

The firm is exclusively interested in companies in the longevity space. In this regard, the firm is most interested in digital technologies including AI, robotics, data analytics, etc. Traditional therapeutics or devices do not fall within their investment priority, as the firm prefers to seek opportunities that leverage digital technologies to deliver novel therapeutic solutions (i.e. digital therapeutics). The firm is open to very early-stage, pre-revenue technologies and are open to university spin-offs/tech transfers.

The firm is backed by co-founders who have entrepreneurial backgrounds and can be a hands-on investor, assisting with company creation and other support as needed. When investing in companies that are not in geographical proximity to the firm, the firm prefers to co-invest alongside larger VC firms.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a venture capital investment firm founded in 2018 and is based in Germany. The firm is actively seeking medtech investment opportunities from Seed to Series B financing rounds, though the firm’s sweet spot is leading Series A investments. Initial check sizes can largely vary; the firm can invest anywhere from €1-5M, and seeks to invest €5-8M over the life of investment. With the current fund, the firm manages 5 portfolio companies, and seeks to invest in ~12 companies, for which the firm estimates 2/3 will be Europe/Israel-based companies, and 1/3 will be USA-based companies. Currently, the firm is not evaluating opportunities outside of USA, Europe, and Israel.

The firm is focused on investing in innovative medical devices that address cardiovascular or neurovascular disease. The firm does not invest in other sectors such as therapeutics, diagnostics, or digital health. Within medical devices, the firm is open to both pre-clinical (prototype) and clinical technologies. The firm has primarily evaluated PMA devices but is open to 510k regulatory pathways. The firm may consider other types of devices on a highly selective basis, but even such opportunities must have some connection or relevance to cardiovascular disease.

The firm prefers to lead investment rounds and seek board representation, though the firm can also co-invest alongside syndicates. Through the firm’s relationship with a proprietary commercialization and distribution platform, the firm is uniquely positioned to create value for their portfolio companies in the European market. Through this sister company relationship, the firm has access to a wide network including over 200 European hospitals, clinical sites, physicians, KOLs, etc. and can provide strategic advice on market strategy (EU clinical trials, regulatory process, reimbursement).

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.